Drug intelligence / Profile preview

Lizi Compound Capsule

Development stage: Preclinical
Lead developer: Affiliated Hospital of Hunan Academy of Traditional Chinese Medicine
Administration: Oral

Overview

Lizi Compound Capsule is a traditional Chinese medicine (TCM) compound preparation developed by The Affiliated Hospital of Hunan Academy of Traditional Chinese Medicine. It is primarily investigated for the treatment of sepsis-associated acute lung injury (SALI) and acute respiratory distress syndrome (ARDS). The formulation is based on TCM principles to regulate the body's response to systemic inflammation and protect lung tissue. In clinical studies, it is administered alongside conventional care to evaluate its efficacy in improving clinical outcomes and safety in adult patients with SALI. The preparation is also referred to as Lizi Compound Decoction in some clinical contexts.

Other names: Lizi Compound Decoction

Beyond the preview

Go deeper on Lizi Compound Capsule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lizi Compound Capsule.

Explore the full profile